Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × magrolimab × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Myeloid Malignancies 1 Multiple Myeloma 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Colorectal Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1 dalpiciclib 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04827576 2025-05-08

ELEVATELung&UC

Gilead Sciences

Phase 2 Terminated

106 enrolled 22 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡